Holen Sie sich die Stockscreener-App
0.3413
1.58%
0.0053
Vorhandelsmarkt:
.34
-0.0013
-0.38%
Schlusskurs vom Vortag:
$0.336
Offen:
$0.336
24-Stunden-Volumen:
1.22M
Relative Volume:
2.06
Marktkapitalisierung:
$19.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-123.46M
KGV:
-0.1318
EPS:
-2.59
Netto-Cashflow:
$-104.11M
1W Leistung:
-13.35%
1M Leistung:
-14.97%
6M Leistung:
-31.53%
1J Leistung:
-80.39%
1-Tages-Spanne:
$0.3254
$0.3665
1-Wochen-Bereich:
$0.3254
$0.4199
52-Wochen-Spanne:
$0.2601
$2.525
Bioatla Inc Stock (BCAB) Company Profile
Firmenname
Bioatla Inc
Sektor
Branche
Telefon
858-558-0708
Adresse
11085 TORREYANA ROAD, SAN DIEGO
Vergleichen Sie BCAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.3413 | 23.01M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2022-09-15 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-05-05 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-21 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-06-28 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | BTIG Research | Buy |
| 2021-01-11 | Eingeleitet | Credit Suisse | Outperform |
| 2021-01-11 | Eingeleitet | JP Morgan | Overweight |
| 2021-01-11 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Bioatla Inc Aktie (BCAB) Neueste Nachrichten
BioAtla Inc. Stock Analysis and ForecastFree Stock Index Interpretation - jammulinksnews.com
Is Now The Time To Buy BioAtla Inc (NASDAQ: BCAB) Stock? - Stocksregister
Is BioAtla Inc. stock a good hedge against inflationFree Consultation - Newser
What drives BioAtla Inc. stock priceStrongest growth potential - jammulinksnews.com
Is BioAtla Inc. a good long term investmentConsistently superior profits - Autocar Professional
What analysts say about BioAtla Inc. stock outlookFast Gains With Reduced Risk - beatles.ru
What analysts say about BioAtla Inc. stockFree Stock Selection - jammulinksnews.com
BioAtla Announces Upcoming Oral Presentation at the 2025 European Society for Medical Oncology (ESMO) TAT Asia Meeting - The Manila Times
What makes BioAtla Inc. stock price move sharplyTrending Stock Alert - Newser
Why BioAtla Inc. stock attracts strong analyst attentionStable Stocks With High Yield - Newser
How BioAtla Inc. stock performs during market volatilityPortfolio Boosting Stock Alerts - Newser
BioAtla (NASDAQ:BCAB) Stock Price Up 2.6% – Here’s Why - Defense World
BioAtla presents Phase I data of BA3182 for metastatic adenocarcinoma - Yahoo Finance
BioAtla Approves 2025 Corporate Bonus Plan - TipRanks
BioAtla, Inc. (NASDAQ:BCAB) Shares Purchased by Two Sigma Investments LP - Defense World
Jane Street Group LLC Purchases 100,204 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla, Inc. (NASDAQ:BCAB) Stock Position Lowered by Two Sigma Advisers LP - Defense World
Millennium Management LLC Cuts Stock Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Upgraded by Wall Street Zen to Hold Rating - Defense World
BioAtla presents Phase 2 Oz-V clinical trial data at ASCO 2025 - MSN
Why Did BioAtla Inc (NASDAQ: BCAB) Drop So Much? - Stocksregister
BioAtla reports promising trial results for cancer drug By Investing.com - Investing.com South Africa
BioAtla reports promising trial results for cancer drug - Investing.com
BioAtla (BCAB) Showcases Promising Data for Ozuriftamab Vedotin in Key Cancer Trial | BCAB Stock News - GuruFocus
BioAtla Presents Phase 2 Ozuriftamab Vedotin (Oz-V) Clinical Trial Data Demonstrating Compelling Antitumor Activity in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC) at the 1.8 mg/kg Q2W dosing regimen - The Manila Times
BioAtla's New Cancer Drug Achieves 13x Better Response Rate Than Standard Treatment in Phase 2 Trial - Stock Titan
BioAtla’s SWOT analysis: CAB platform stock faces pivotal year amid clinical trials - Investing.com Nigeria
Dimensional Fund Advisors LP Sells 86,264 Shares of BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla receives Nasdaq delisting warning By Investing.com - Investing.com India
BioAtla receives Nasdaq delisting warning - Investing.com Australia
Finanzdaten der Bioatla Inc-Aktie (BCAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):